Exclusive Summary

• Clear Best-in-Class Positioning: As a high-purity synthetic polypeptide, UB631 fundamentally addresses the core vulnerabilities of natural ACTH (the current standard of care) regarding safety (viral risk, immunogenicity) and supply chain stability.
• Robust Pre-clinical Evidence & Safety Advantage: Pre-clinical data indicate that UB631 may achieve comparable efficacy to natural ACTH at a lower dose, while avoiding the risk of irreversible visual impairment associated with its competitor, Vigabatrin, offering a superior safety profile.
• Validated Early Development & Clear Global Regulatory Path: The project has completed Phase I clinical trials and has been granted a core compound patent in the U.S. It also has the potential to apply for expedited pathways (e.g., Orphan Drug Designation, Priority Review) in key global markets, significantly de-risking co-development.
• Immense Market & Expansion Potential: It precisely targets the high-value infantile spasms market (a theoretical market of over $800M in the U.S.) and, thanks to its safety advantages, is poised for future expansion into broader autoimmune indications like multiple sclerosis and rheumatoid arthritis.